{"id":"NCT03285594","sponsor":"Lexicon Pharmaceuticals","briefTitle":"Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition to Oral Antidiabetes Drugs (OADs)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-15","primaryCompletion":"2019-09-17","completion":"2019-09-27","firstPosted":"2017-09-18","resultsPosted":"2021-05-11","lastUpdate":"2021-05-11"},"enrollment":571,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Sotagliflozin","otherNames":["SAR439954"]},{"type":"DRUG","name":"Insulin glargine (HOE901)","otherNames":["Lantus"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Oral Antidiabetes Drugs (OADs)","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Sotagliflozin 200 mg","type":"EXPERIMENTAL"},{"label":"Sotagliflozin 400 mg","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo demonstrate the superiority of sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1C (HbA1c) reduction in participants with type 2 diabetes mellitus (T2D) who have inadequate glycemic control on basal insulin alone or with oral antidiabetes drugs (OADs).\n\nSecondary Objectives:\n\n* To assess the effects of sotagliflozin 400 mg versus placebo on fasting plasma glucose (FPG), body weight, systolic blood pressure (SBP), and HbA1c.\n* To assess the effects of sotagliflozin 200 mg versus placebo on HbA1c, body weight, FPG, and SBP.\n* To evaluate the safety of sotagliflozin 400 and 200 mg versus placebo.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18","timeFrame":"Baseline and Week 18","effectByArm":[{"arm":"Placebo","deltaMin":-0.27,"sd":0.073},{"arm":"Sotagliflozin 200 mg","deltaMin":-0.72,"sd":0.073},{"arm":"Sotagliflozin 400 mg","deltaMin":-0.81,"sd":0.056}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":23},"locations":{"siteCount":106,"countries":["United States","Bulgaria","Canada","Czechia","France","Hungary","Slovakia","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":144},"commonTop":["Nasopharyngitis","Urinary tract infection","Vitamin D deficiency","Upper respiratory tract infection"]}}